Myelodysplastic syndromes: the challenge of developing clinical guidelines and supportive care strategies for a rare disease.
Myelodysplastic syndromes (MDS) represent a group of clonal myeloid malignancies with variability in clinical presentation and disease trajectory, as well as prognosis and treatment recommendations (Kurtin & Demakos, 2010). MDS is considered to be a rare disease that is most common in adults older than age 70. The disease is characterized by ineffective hematopoiesis, progressive bone marrow failure, and a variable risk of leukemic transformation thought to result from complex interactions between the malignant clone and the bone marrow microenvironment (Kurtin, 2011). This supplement is intended to provide the oncology clinician with an overview of MDS and provide tools for the clinical management and support of patients with MDS.
University of Arizona Cancer Center, USA. sandra.kurtin@uahealth.com
Sandra E
SE
Kurtin
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007857:Leadership; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000453:epidemiology / Q000451:nursing*; D009859:Oncology Nursing; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011379:Prognosis; D018426:SEER Program; D014481:United States / Q000453:epidemiology
D000970:Antineoplastic Agents